Related Experiment Video

Updated: Jun 18, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

399

Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy

Xing Ma1, Yangyang Zhou2, Ruping Li1

  • 1Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Molecular Carcinogenesis
|August 2, 2024
PubMed

Insights

Dysregulated Hippo/Yes-associated protein (YAP) signaling is key in intrahepatic cholangiocarcinoma (ICC) development. Targeting this pathway offers new therapeutic strategies for ICC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Intrahepatic cholangiocarcinoma (ICC) tumorigenesis is significantly linked to the Hippo/Yes-associated protein (YAP) signaling pathway.
  • The Hippo/YAP pathway is a crucial regulator of both normal physiological processes and oncogenic activities.

Purpose of the Study:

  • To review recent research on the disrupted Hippo/YAP pathway in ICC.
  • To explore the diagnostic potential of key genes within this pathway.
  • To identify therapeutic opportunities targeting the Hippo/YAP pathway in ICC.

Main Methods:

  • Comprehensive literature review of studies on Hippo/YAP signaling in ICC.
  • Analysis of mechanisms underlying Hippo/YAP dysregulation in ICC.
  • Evaluation of diagnostic markers and therapeutic targets within the pathway.

Main Results:

  • The Hippo/YAP pathway's aberrant activity is a critical factor in ICC initiation and progression.
  • Specific genes in the Hippo/YAP pathway show potential as diagnostic biomarkers for ICC.
  • The pathway presents a promising target for novel molecular therapies against ICC.

Conclusions:

  • The Hippo/YAP pathway is a central player in intrahepatic cholangiocarcinoma.
  • Understanding Hippo/YAP dysregulation provides avenues for improved ICC diagnostics.
  • Targeting the Hippo/YAP pathway represents a significant therapeutic opportunity for ICC treatment.
Keywords:
Hippo/YAPHippo/Yes‐associated proteindiagnosisintrahepatic cholangiocarcinomatherapy

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.8K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K